X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (934) 934
index medicus (922) 922
myeloablative agonists - therapeutic use (726) 726
male (674) 674
female (670) 670
hematology (659) 659
transplantation (623) 623
adult (541) 541
middle aged (525) 525
immunology (460) 460
transplantation conditioning - methods (417) 417
transplantation, homologous (396) 396
adolescent (376) 376
bone-marrow-transplantation (331) 331
hematopoietic stem cells (331) 331
hematopoietic stem cell transplantation (321) 321
stem cells (321) 321
hematology, oncology and palliative medicine (309) 309
treatment outcome (305) 305
aged (304) 304
survival analysis (280) 280
child (261) 261
oncology (257) 257
retrospective studies (256) 256
transplantation conditioning (231) 231
child, preschool (211) 211
versus-host-disease (204) 204
hematopoietic stem cell transplantation - methods (202) 202
stem-cell transplantation (184) 184
myeloablative agonists - administration & dosage (175) 175
graft vs host disease - prevention & control (174) 174
vidarabine - analogs & derivatives (170) 170
recurrence (166) 166
young adult (165) 165
hematopoietic stem cell transplantation - adverse effects (164) 164
analysis (160) 160
chemotherapy (160) 160
hematologic neoplasms - therapy (158) 158
myeloablative agonists - adverse effects (151) 151
infant (149) 149
unrelated donors (147) 147
graft vs host disease - mortality (143) 143
health aspects (142) 142
care and treatment (139) 139
bone marrow (138) 138
mortality (136) 136
cancer (135) 135
disease-free survival (133) 133
transplantation, autologous (133) 133
graft vs host disease - immunology (130) 130
leukemia (125) 125
article (120) 120
vidarabine - therapeutic use (120) 120
immunosuppressive agents - therapeutic use (117) 117
risk factors (116) 116
transplantation conditioning - adverse effects (114) 114
prognosis (112) 112
stem cell transplantation (110) 110
acute myeloid-leukemia (109) 109
graft vs host disease - pathology (107) 107
busulfan - therapeutic use (104) 104
melphalan - therapeutic use (103) 103
therapy (103) 103
children (102) 102
cyclophosphamide (101) 101
leukemia, myeloid, acute - therapy (100) 100
hematologic neoplasms - immunology (98) 98
busulfan (96) 96
cyclophosphamide - therapeutic use (96) 96
follow-up studies (95) 95
hematologic neoplasms - mortality (95) 95
busulfan - administration & dosage (93) 93
histocompatibility testing (93) 93
graft vs host disease - etiology (91) 91
prospective studies (88) 88
fludarabine (87) 87
survival (85) 85
survival rate (84) 84
remission induction (83) 83
research (83) 83
antineoplastic combined chemotherapy protocols - therapeutic use (82) 82
acute disease (81) 81
hematologic neoplasms - pathology (79) 79
siblings (79) 79
combined modality therapy (75) 75
risk (74) 74
time factors (74) 74
total-body irradiation (74) 74
graft survival (72) 72
pediatrics (72) 72
patient outcomes (69) 69
hematopoietic stem cell transplantation - mortality (67) 67
whole-body irradiation (66) 66
hematologic malignancies (65) 65
leukemia, myeloid, acute - mortality (65) 65
multiple myeloma - therapy (65) 65
abridged index medicus (64) 64
bone marrow transplantation (64) 64
dosage and administration (63) 63
t cells (61) 61
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (941) 941
French (5) 5
Spanish (3) 3
Russian (2) 2
Chinese (1) 1
Czech (1) 1
Danish (1) 1
German (1) 1
Hungarian (1) 1
Japanese (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2015, Volume 33, Issue 32, pp. 3741 - 3749
Journal Article
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 12, pp. 2039 - 2051
Abstract In contrast to the upfront setting in which the role of high-dose therapy with autologous hematopoietic cell transplantation (HCT) as consolidation of... 
Hematology, Oncology and Palliative Medicine | Stem cell transplantation | Myeloma | Salvage therapy | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE | COMBINATION THERAPY | LENALIDOMIDE PLUS DEXAMETHASONE | AUTOLOGOUS TRANSPLANTATION | FOLLOW-UP | RISK | IMMUNOLOGY | TRANSPLANTATION | ALLOGENEIC TRANSPLANTATION | MAINTENANCE | RANDOMIZED PHASE-III | HEMATOLOGY | LOW-DOSE DEXAMETHASONE | Myeloablative Agonists - therapeutic use | Recurrence | Humans | Antibodies, Monoclonal - therapeutic use | Multiple Myeloma - immunology | Transplantation, Autologous | Bone Marrow Transplantation - methods | Remission Induction | Proteasome Inhibitors - therapeutic use | Transplantation, Homologous | Randomized Controlled Trials as Topic | Multiple Myeloma - pathology | Multiple Myeloma - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Salvage Therapy - methods | Immunologic Factors - therapeutic use | Relapse | Multiple myeloma | Bone marrow | Clinical trials | Transplantation | Conferences and conventions | Hematopoietic stem cells | Trade and professional associations | Diseases | Index Medicus | Clinical Medicine | Hematologi | Medical and Health Sciences | Hematology | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 6, pp. 701 - 709
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2014, Volume 20, Issue 10, pp. 1573 - 1579
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 6, pp. 1046 - 1053
Abstract There are limited data to guide the choice of high-dose therapy (HDT) regimen before autologous hematopoietic cell transplantation (AHCT) for patients... 
Hematology, Oncology and Palliative Medicine | Idiopathic pneumonia syndrome | Autologous transplantation | Lymphoma | RISK-FACTORS | PROGNOSTIC-FACTORS | SPANISH COOPERATIVE GROUP | CYCLOPHOSPHAMIDE | BONE-MARROW-TRANSPLANTATION | Idiopathic pneumonia | PREPARATIVE REGIMENS | IMMUNOLOGY | CHEMOTHERAPY | TRANSPLANTATION | ETOPOSIDE | syndrome | DISEASE | NON-HODGKINS-LYMPHOMA | HEMATOLOGY | Myeloablative Agonists - therapeutic use | Lymphoma, Non-Hodgkin - immunology | Whole-Body Irradiation | Cytarabine - therapeutic use | Hodgkin Disease - pathology | Humans | Middle Aged | Male | Transplantation, Autologous | Melphalan - therapeutic use | Cyclophosphamide - therapeutic use | Lymphoma, Non-Hodgkin - pathology | Carmustine - therapeutic use | Aged, 80 and over | Hodgkin Disease - mortality | Adult | Female | Registries | Retrospective Studies | Transplantation Conditioning - methods | Busulfan - therapeutic use | Drug Administration Schedule | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Lymphoma, Non-Hodgkin - therapy | Hodgkin Disease - therapy | Adolescent | Survival Analysis | Hodgkin Disease - immunology | Aged | Lymphoma, Non-Hodgkin - mortality | Care and treatment | Patient outcomes | Analysis | Mortality | Lymphomas | Transplantation | Hematopoietic stem cells | Index Medicus | idiopathic pneumonia syndrome | autologous transplant | lymphoma
Journal Article
Science, ISSN 0036-8075, 11/2009, Volume 326, Issue 5954, pp. 818 - 823
X-linked adrenoleukodystrophy (ALD) is a severe brain demyelinating disease in boys that is caused by a deficiency in ALD protein, an adenosine... 
Myeloid cells | Genetic vectors | Demyelinating diseases | B lymphocytes | Stem cells | Hematocrit | Cell lines | Gene therapy | Cells | Hematopoietic stem cells | Research Article | HIV VECTORS | SEVERE COMBINED IMMUNODEFICIENCY | INTEGRATION SITE SELECTION | MICROGLIA | BONE-MARROW-TRANSPLANTATION | HUMAN CD34(+) CELLS | MULTIDISCIPLINARY SCIENCES | MOUSE MODEL | NOD/SCID MICE | LONG-TERM ENGRAFTMENT | DIFFERENTIATE | Myeloablative Agonists - therapeutic use | Genetic Therapy | Leukocytes, Mononuclear - metabolism | Microglia - metabolism | Humans | Adrenoleukodystrophy - pathology | Male | Transplantation, Autologous | ATP-Binding Cassette Transporters - genetics | Hematopoiesis | Adrenoleukodystrophy - therapy | Hematopoietic Stem Cells - physiology | Female | Cell Differentiation | Fatty Acids - blood | Hematopoietic Stem Cells - virology | Child | Microglia - cytology | Gene Expression | Transduction, Genetic | Hematopoietic Stem Cell Transplantation | ATP Binding Cassette Transporter, Sub-Family D, Member 1 | HIV-1 - genetics | Virus Integration | Disease Progression | Cell Lineage | Animals | Brain - pathology | Mice | Adrenoleukodystrophy - genetics | Transplantation Conditioning | Genetic Vectors | Usage | Care and treatment | Adrenoleukodystrophy | Patient outcomes | Transplantation | Health aspects | Viruses | Genetic disorders | Neurological disorders | ABCD1 protein | Index Medicus | Life Sciences | Cellular Biology
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 7, pp. 1299 - 1307
Abstract We enrolled 30 patients on a prospective phase II trial utilizing a total body irradiation (TBI)–based myeloablative preparative regimen (fludarabine... 
Hematology, Oncology and Palliative Medicine | Stem cell transplantation | Myeloablative | Total body irradiation | Haploidentical | Peripheral blood stem cells | HEMORRHAGIC CYSTITIS | BONE-MARROW-TRANSPLANTATION | IMMUNOLOGY | 2-STEP APPROACH | VERSUS-HOST-DISEASE | CONDITIONING REGIMEN | TRANSPLANTATION | REDUCED-INTENSITY | EUROPEAN-GROUP | HIGH-RISK | LEUKEMIA WORKING PARTY | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | Haplotypes | Hematologic Neoplasms - therapy | Myeloablative Agonists - therapeutic use | Recurrence | Whole-Body Irradiation | Prospective Studies | Hematologic Neoplasms - mortality | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Risk | Hematologic Neoplasms - pathology | Graft vs Host Disease - immunology | Cyclophosphamide - therapeutic use | Graft vs Host Disease - mortality | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Unrelated Donors | Graft vs Host Disease - etiology | Acute Disease | Histocompatibility Testing | Transplantation, Isogeneic | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Survival Analysis | Graft vs Host Disease - prevention & control | Hematologic Neoplasms - immunology | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning | Chronic Disease | Leukemia | Immunotherapy | Mortality | Stem cells | Transplantation | Lymphomas | Mycophenolate mofetil | T cells | Index Medicus
Journal Article
by Boelens, Jaap Jan and Boelens, Jaap Jan and Aldenhoven, Mieke and Aldenhoven, Mieke and Purtill, Duncan and Purtill, Duncan and Ruggeri, Annalisa and Ruggeri, Annalisa and Defor, Todd and DeFor, Todd and Wynn, Robert and Wynn, Robert and Wraith, E and Wraith, Ed and Cavazzana-Calvo, Marina and Cavazzana-Calvo, Marina and Rovelli, Attilio and Rovelli, Attilio and Fischer, Alain and Fischer, Alain and Tolar, Jakub and Tolar, Jakub and Prasad, Vinod K and Prasad, Vinod K and Escolar, Maria and Escolar, Maria and Gluckman, Eliane and Gluckman, Eliane and O'Meara, Anne and O’Meara, Anne and Orchard, Paul J and Orchard, Paul J and Veys, Paul and Veys, Paul and Eapen, Mary and Eapen, Mary and Kurtzberg, Joanne and Kurtzberg, Joanne and Rocha, Vanderson and Rocha, Vanderson and Eurocord, Eurocord and Malech, H and Horwitz, E and Inborn Errors Working Party of European Blood and Marrow Transplant group, Errors Working Party of European Blood and Marrow Transplant group and Le-Rademacher, J and Duke University Blood and Marrow Transplantation Program, University Blood and Marrow Transplantation Program and He, W and Centre for International Blood and Marrow Research, for International Blood and Marrow Research and Gaspar, B and Porta, F and Driscoll, T.A and Landi, D.B and Martin, P.L and Page, K.M and Parikh, H and Ctr Int Blood Marrow Res and Duke Univ and Inborn Errors Working Party of European Blood and Marrow Transplant group and Duke University Blood and Marrow Transplantation Program and Eurocord and Centre for International Blood and Marrow Research and on behalf of all participating centers from Eurocord, Inborn Errors Working Party of European Blood and Marrow Transplant group, Duke University, and the Centre for International Blood and Marrow Research
Blood, ISSN 0006-4971, 05/2013, Volume 121, Issue 19, pp. 3981 - 3987
Journal Article